Anacor Pharmaceuticals (NASDAQ:ANAC) is a developmental stage pharmaceutical company with multiple near and long term catalysts. These catalysts have the potential to drive company growth and shareholder value for many years in the future. The catalysts have the potential to create huge upside for investors who are willing to hold onto the stock long term.
The catalysts regarding Tavaborole can be summarized in the following table:
|PDUFA||Mid-2014 (depending on NDA classification)|
|Commercialization Decision||Latter part of 2013|
The first major catalyst is the filing of a New Drug Application (NDA) for Tavaborole, for the treatment of Onychomycosis. Onychomycosis is a rather common condition (a fungal infection of...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|